EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TPP-Thiazole Derivatives Ameliorate Psoriasiform Inflammation by Glycolysis Inhibition

Xinwei Meng, Ci-An Cheng, Zhirui Zhang, Siying Qu, Anqi Zhang, Yang Zhang, Jinxin Gu iD, Hanwen Zhang, Keyue Ding, Lei Fu iD, Mengchen Lu iD, Daiyun Huang und 1 weitere

Molecules · 15.03.2026 · 31 (6) · 982

DOI: 10.3390/molecules31060982 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, online erschienen am 15.03.2026. Verfasst von Xinwei Meng und 12 weiteren Autor:innen. Beteiligte Einrichtung: Wisdom Lake Academy of Pharmacy, Xi'an Jiao Tong Liverpool University, Suzhou 215123, China. Hauptthemen laut MEDLINE: Glycolysis, Thiazoles, Psoriasis, Inflammation. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SIP High-Quality Innovation Platform for Chronic Diseases, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriasis, a chronic inflammatory skin disease, is driven by immune dysregulation and keratinocyte hyperproliferation, with current biologics facing limitations. Emerging evidence points to mitochondrial dysfunction and a pathological shift to aerobic glycolysis as core disease drivers. Here, we report that MitoFu-O, a novel mitochondria-targeting TPP-thiazole derivative, effectively ameliorates psoriasiform inflammation in imiquimod-induced mice and cytokine-stimulated keratinocytes. Mechanistically, MitoFu-O acts by inhibiting pathological glycolysis, downregulating key glycolytic enzymes (HK1, GAPDH, LDHA), and subsequently suppressing the activation of pivotal pro-inflammatory signaling pathways (MAPK, NF-κB, and STAT3). Our findings establish targeted mitochondrial modulation as a potent therapeutic strategy, positioning MitoFu-O as a promising lead compound that acts upstream of cytokine signaling by normalizing the metabolic reprogramming fundamental to psoriatic pathogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlycolysisThiazolesPsoriasisInflammationAnti-Inflammatory AgentsAnimalsMiceHumansKeratinocytesSignal TransductionMitochondriaImiquimodDisease Models, AnimalCytokines

Stichwörter der Autor:innen

TPP-thiazole derivativesglycolysis inhibitionimmune-metabolic regulationmitochondriapsoriasiform inflammation

Substanzen

ThiazolesImiquimodCytokinesAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Wisdom Lake Academy of Pharmacy, Xi'an Jiao Tong Liverpool University, Suzhou 215123, China.
  • School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.
  • Department of Medicinal Chemistry, College of Pharmaceutical Sciences, Soochow University Medical College, Suzhou 215123, China.

ORCID-Profile: Jinxin Gu, Lei Fu, Mengchen Lu

Förderung

  • SIP High-Quality Innovation Platform for Chronic Diseases
  • National Natural Science Foundation of China

Zitieren

APA

Meng, X., Cheng, C. A., Zhang, Z., Qu, S., Zhang, A., Zhang, Y., Gu, J., Zhang, H., Ding, K., Fu, L., Lu, M., Huang, D., & Qiao, Y. (2026). TPP-Thiazole Derivatives Ameliorate Psoriasiform Inflammation by Glycolysis Inhibition. Molecules, 31(6), 982. https://doi.org/10.3390/molecules31060982

Vancouver

Meng X, Cheng CA, Zhang Z, Qu S, Zhang A, Zhang Y, et al. TPP-Thiazole Derivatives Ameliorate Psoriasiform Inflammation by Glycolysis Inhibition. Molecules. 2026;31(6):982. doi:10.3390/molecules31060982

BibTeX
@article{Meng2026,
  author = {Meng, Xinwei and Cheng, Ci-An and Zhang, Zhirui and Qu, Siying and Zhang, Anqi and Zhang, Yang and Gu, Jinxin and Zhang, Hanwen and Ding, Keyue and Fu, Lei and Lu, Mengchen and Huang, Daiyun and Qiao, Yixue},
  title = {TPP-Thiazole Derivatives Ameliorate Psoriasiform Inflammation by Glycolysis Inhibition},
  journal = {Molecules},
  year = {2026},
  volume = {31},
  number = {6},
  pages = {982},
  doi = {10.3390/molecules31060982}
}
Kostenlos starten →